Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.

Trial Details

NCT ID
NCT07033572
Phase
NA
Sponsor
Fujian Medical University
Status
RECRUITING
Cancer Type
Papillary Thyroid Cancer
Interventions
  • Endoscopic Hemithyroidectomy with Central-Neck Dissection
  • Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

  • Age 18-65 years.
  • Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.
  • Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.
  • No radiologic lymph-node metastasis on contralateral side.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Papillary Thyroid Cancer Trials on Trialify →